HomeComparePCOFF vs ABBV

PCOFF vs ABBV: Dividend Comparison 2026

PCOFF yields 3.03% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PCOFF wins by $1.66M in total portfolio value· pulled ahead in Year 4
10 years
PCOFF
PCOFF
● Live price
3.03%
Share price
$0.33
Annual div
$0.01
5Y div CAGR
66.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.76M
Annual income
$1,271,748.38
Full PCOFF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — PCOFF vs ABBV

📍 PCOFF pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPCOFFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PCOFF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PCOFF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PCOFF
Annual income on $10K today (after 15% tax)
$257.58/yr
After 10yr DRIP, annual income (after tax)
$1,080,986.12/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, PCOFF beats the other by $1,059,930.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PCOFF + ABBV for your $10,000?

PCOFF: 50%ABBV: 50%
100% ABBV50/50100% PCOFF
Portfolio after 10yr
$933.2K
Annual income
$648,260.07/yr
Blended yield
69.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

PCOFF
No analyst data
Altman Z
3.9
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PCOFF buys
0
ABBV buys
0
No recent congressional trades found for PCOFF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPCOFFABBV
Forward yield3.03%3.06%
Annual dividend / share$0.01$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR66.9%40.6%
Portfolio after 10y$1.76M$102.3K
Annual income after 10y$1,271,748.38$24,771.77
Total dividends collected$1.70M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PCOFF vs ABBV ($10,000, DRIP)

YearPCOFF PortfolioPCOFF Income/yrABBV PortfolioABBV Income/yrGap
1$11,206$505.76$11,550$430.00$344.00ABBV
2$12,874$884.01$13,472$627.96$598.00ABBV
3$15,360$1,584.19$15,906$926.08$546.00ABBV
4← crossover$19,383$2,948.07$19,071$1,382.55+$312.00PCOFF
5$26,543$5,802.95$23,302$2,095.81+$3.2KPCOFF
6$40,796$12,395.03$29,150$3,237.93+$11.6KPCOFF
7$73,367$29,716.01$37,536$5,121.41+$35.8KPCOFF
8$161,862$83,359.01$50,079$8,338.38+$111.8KPCOFF
9$460,051$286,858.47$69,753$14,065.80+$390.3KPCOFF
10$1,764,003$1,271,748.38$102,337$24,771.77+$1.66MPCOFF

PCOFF vs ABBV: Complete Analysis 2026

PCOFFStock

Pico Far East Holdings Limited, an investment holding company, engages in the exhibition, event, and brand activation; visual branding activation; museum, themed environment, interior, and retail; meeting architecture activation; and related businesses. It offers visual branding solutions, brand management, and design and consultancy services; digital marketing and technology; visual and digital content; virtual and online solutions; design and production management; event management; interior renovation, promotion, exhibition and event fabrication, electrical specialist, corporate, and image consultancy and project management; and construction, interior designing, decoration, and turnkey services, as well as technology solutions for exhibitions, events, museums, and interior and themed environment. The company also provides design, lifestyle, and business innovation communications agency services; designs, develops, operates, and manages exhibition and convention center; produces exhibition, event, and interior fit-out products; and organizes and manages exhibitions, conferences, trade fairs, convention conferences, seminars, and events. In addition, it offers freight forwarding, exhibition logistics, and transportation services for exhibitors; media planning, procurement, and optimization services in social video; services to organizers; and exhibition booth fabrication, event planning, design consultancy, themed designing, brand marketing and creative agency, brand strategy, engagement marketing, and public relations services. Further, the company manufactures and installs exhibitions; and offers services and disruptive technologies, design and technology solutions for interactive experience, and management development programs and courses. It also holds properties. The company operates in Greater China, the Middle East, Southeast Asia, the United Kingdom, the United States, and internationally. The company was founded in 1969 and is based in Tai Po, Hong Kong.

Full PCOFF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this PCOFF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PCOFF vs SCHDPCOFF vs JEPIPCOFF vs OPCOFF vs KOPCOFF vs MAINPCOFF vs JNJPCOFF vs MRKPCOFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.